Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.

Amazon Pharmacy’s debut in India could recalibrate and disrupt drug dispensing and distribution in the country, while also tempering investment flow in the e-pharmacy segment. Some experts also predict a squeeze on pharma’s profits.

Scrip delves into some key trends that could play out in 2020 to shape and impact Indian pharmaceutical firms. Keep an eye on opportunities in key markets like China and the US, and on private equity interest in “control deals” and trade margin-related tweaks on the Indian market.